The NHS may soon be able to identify your risk of heart disease or a stroke well before it happens by studying your DNA.

Genetic testing is on the cusp of a major revolution, which has the potential to shift not just how we understand our risk for disease, but how we practice healthcare. In the clinic today, genetic testing is used only in cases where we know that mutations have big impact on physiology (BRCA mutations in breast cancer, for example). But our knowledge of how our genetics influences our risk for disease has evolved, and we now know that many (tens of thousands to even millions) small changes in our genes, each of which individually has a tiny effect, combine to influence our risk profile. This new appreciation — coupled with powerful statistical methods and massive datasets — has fueled the creation of a new tool to quantify the risk of a broad range of common diseases: the polygenic risk score. On this episode, host Lauren Richardson is joined by Professor Peter Donnelly and Vineeta Agarwala to discuss these scores and how they can reshape healthcare, away from a paradigm of treating illness and towards prevention and maintenance of health.

Predictive genomics to power the future of population and personalised health.

Peter discusses AI and breast cancer diagnosis and the potential to use genetics to understand an individual’s risk for all common disease.

©BBC 2022, All rights reserved, Used with permission.

Genomics Plc releases results showing the extent to which predictive DNA tests can reveal the likelihood of diseases from cancers to asthma and coronary heart disease.

The company that carried out Hancock’s test, Genomics Plc, has developed similar genetic risk tests for a range of other common conditions including coronary heart disease, breast cancer, asthma and diabetes.

The NHS may soon be able to identify your risk of heart disease or a stroke well before it happens by studying your DNA.

Genetic testing is on the cusp of a major revolution, which has the potential to shift not just how we understand our risk for disease, but how we practice healthcare. In the clinic today, genetic testing is used only in cases where we know that mutations have big impact on physiology (BRCA mutations in breast cancer, for example). But our knowledge of how our genetics influences our risk for disease has evolved, and we now know that many (tens of thousands to even millions) small changes in our genes, each of which individually has a tiny effect, combine to influence our risk profile. This new appreciation — coupled with powerful statistical methods and massive datasets — has fueled the creation of a new tool to quantify the risk of a broad range of common diseases: the polygenic risk score. On this episode, host Lauren Richardson is joined by Professor Peter Donnelly and Vineeta Agarwala to discuss these scores and how they can reshape healthcare, away from a paradigm of treating illness and towards prevention and maintenance of health.

Predictive genomics to power the future of population and personalised health.

Peter discusses AI and breast cancer diagnosis and the potential to use genetics to understand an individual’s risk for all common disease.

©BBC 2022, All rights reserved, Used with permission.

Genomics Plc releases results showing the extent to which predictive DNA tests can reveal the likelihood of diseases from cancers to asthma and coronary heart disease.

The company that carried out Hancock’s test, Genomics Plc, has developed similar genetic risk tests for a range of other common conditions including coronary heart disease, breast cancer, asthma and diabetes.

The NHS may soon be able to identify your risk of heart disease or a stroke well before it happens by studying your DNA.

Genetic testing is on the cusp of a major revolution, which has the potential to shift not just how we understand our risk for disease, but how we practice healthcare. In the clinic today, genetic testing is used only in cases where we know that mutations have big impact on physiology (BRCA mutations in breast cancer, for example). But our knowledge of how our genetics influences our risk for disease has evolved, and we now know that many (tens of thousands to even millions) small changes in our genes, each of which individually has a tiny effect, combine to influence our risk profile. This new appreciation — coupled with powerful statistical methods and massive datasets — has fueled the creation of a new tool to quantify the risk of a broad range of common diseases: the polygenic risk score. On this episode, host Lauren Richardson is joined by Professor Peter Donnelly and Vineeta Agarwala to discuss these scores and how they can reshape healthcare, away from a paradigm of treating illness and towards prevention and maintenance of health.

Predictive genomics to power the future of population and personalised health.

Peter discusses AI and breast cancer diagnosis and the potential to use genetics to understand an individual’s risk for all common disease.

©BBC 2022, All rights reserved, Used with permission.

Genomics Plc releases results showing the extent to which predictive DNA tests can reveal the likelihood of diseases from cancers to asthma and coronary heart disease.

The company that carried out Hancock’s test, Genomics Plc, has developed similar genetic risk tests for a range of other common conditions including coronary heart disease, breast cancer, asthma and diabetes.